Search

Editors

Harry Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Richard L. Cassin Editor at Large

Elizabeth K. Spahn Editor Emeritus 

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor


FCPA Blog Daily News

Entries in GlaxoSmithKline (40)

Thursday
Feb282019

Giant corporations are good for compliance

Most of us, if we have any sense at all, harbor some healthy distrust of the world's biggest companies. For good reason we fear the concentrated power of giant corporations. What, after all, is one person compared to the overwhelming might of Facebook, Walmart, or Exxon?

Click to read more ...

Monday
Feb252019

UK ends graft investigations of GSK and individuals at Rolls-Royce

The UK Serious Fraud Office said Friday it has closed bribery investigations into UK-based GlaxoSmithKline PLC and individuals at subsidiaries of Rolls-Royce Holdings PLC.

Click to read more ...

Wednesday
Feb132019

China healthcare compliance is still a ‘donations’ minefield

It has been over five years since the start of the GlaxoSmithKline case that rocked the China healthcare industry. At the time, compliance, audit and legal teams were shocked by the prevalence of integrity and corruption issues that had apparently gone unidentified, despite the widespread practice of generating slush funds through fraudulent travel expense claims.

Click to read more ...

Thursday
Feb082018

Feds open new GSK China bribery investigation

GlaxoSmithKline said in a securities filing Wednesday that the DOJ and SEC asked for information about third-party advisers the company hired in China during a corruption investigation there.

Click to read more ...

Monday
Oct022017

Federal judge tosses China investigators’ RICO claims against GSK

A federal judge in Philadelphia Friday dismissed a civil complaint against UK-based GlaxoSmithKline brought by a British private investigator and his American wife and their China-based company.

Click to read more ...

Wednesday
Nov022016

NYT Report: GSK ignored whistleblower who reported China fraud and bribery

A report by David Barboza of the New York Times details how an apparently highly-placed whistleblower in GlaxoSmithKline's China operation sent the head office in London a series of long, well-written memos about illegal sales practices that directors, executives, and auditors chose to ignore.

Click to read more ...

Friday
Sep302016

GSK pays SEC $20 million to settle China FCPA violations

The Securities and Exchange Commission said Friday UK-based pharma GlaxoSmithKline plc will pay a $20 million civil penalty to settle charges that it violated the Foreign Corrupt Practices Act when China-based subsidiaries spent millions of dollars on pay-to-prescribe schemes for several years to pump up sales.

Click to read more ...

Thursday
Jan212016

DOJ indicts China scientists for alleged GSK trade secrets ripoff

The U.S. Attorney’s Office for the Eastern District of Pennsylvania filed an indictment Wednesday charging five people in an alleged scheme to steal trade secrets from pharma giant GlaxoSmithKline. 

Click to read more ...

Monday
Jun222015

Alison Taylor: Does competition cause corruption?

You might expect corrupt companies to downplay and devalue the principles of market competition. In fact the opposite is true.

Click to read more ...

Monday
Jun152015

Peter Humphrey and wife released from prison

British investigator Peter Humphrey and his American wife Yu Yingzeng have been released early from prison in China.

Click to read more ...

Thursday
May282015

Pharma news: China restricts hospital drug sales 

China is pushing reforms at public hospitals in the wake of widespread complaints about inadequate healthcare services and corruption related to drug sales.

Click to read more ...

Thursday
Mar052015

Managing compliance in China's emerging new civilization

President Xi Jinping visits UNESCO in Paris in 2014A new phase has begun in the maturation of China as an economic superpower, an era that President Xi Jinping has taken to calling “the new normal.” The ongoing challenge for Beijing is to transition from a largely investment-propelled, export-oriented economy to one increasingly driven by consumption.

Click to read more ...